In their report, they should give a description of how they transmit their information to the druggists and physicians in the country as a whole, with particular reference to their advertising brochures.

In this connection I might mention three names:

Dr. Armand Frappier, Directeur. Institut de Microbiologie et d'Hygiène de l'Université de Montréal, Dr. J. Parker, Director, Research, Chas. E. Frost and Co., Montreal, Dr. J. D. McColl, Director, Pharmacological Research, Frank W. Horner Limited.

There is another list of manufacturers and professional people that your chairman has at his disposal, which can be used to facilitate our investigation.

2. (*d*) Pharmaceutical manufacturers should provide the Committee with a report on these practices in respect of the clinical trials which are carried out in advance of the general release of new drugs. This report should cover at least the following:

(i) Information on their selection of clinical investigators, for example, what is their criteria of acceptability for the selection of qualified investigators?

What part does the manufacturer's representative play in actually planning the clinical trial?

Are these trials carried out in hospitals?

What is the criteria of acceptability for a new drug?

(ii) Any specific recommendations concerning existing legislation on new drugs on which they would like to comment pertaining particularly to the safety element.

There are two names for your consideration here, Dr. K. K. Ferguson, Director, Connaught Laboratories, Toronto, Ontario and Dr. L. Smith, Medical Director, Ayerst, McKenna and Harrison Limited, Montreal, Quebec.

The references are the same as I have read out for section 2 (c), pertaining to the other witnesses that may be called.

2. (*e*) Any expert or experts in clinical medicine should be called to give an appraisal of existing requirements respecting the preclinical and clinical testing of drugs before their release for general use. He, or they, should answer such questions relating to, for example, are we doing all that can be done in our preclinical and clinical testing of drugs to safeguard the public and so on?

There are three gentlemen indicated here who are eminent in the field in the United States. I have a list of Canadian people but it is very lengthy and that is why I did not incorporate it in this statement. We have: Dr. J. T. Litchfield, Director, Experimental Therapeutic Research Section, Lederle Laboratories, New York, Dr. J. Holland, Medical Director, American Home Products, New York and Dr. K. K. Chan, Director, Pharmacological Research, Eli Lilly and Company, Indianapolis.

We have an extensive list of eminent doctors and professors in Canada whom the committee may like to consider at a later date.

2. (*f*) Pharmaceutical manufacturers should be requested to present to the committee the various methods which are used to promote the sale of drugs in Canada. Such methods as advertising, labelling and detailing of drugs, and qualifications of drug representatives in the field should be examined by the committee. Consideration of their quality control practices would be advisable.

(i) Canadian Pharmaceutical Manufacturers Association.

(ii) Canadian Pharmaceutical Association.